-
1
-
-
0027370108
-
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
-
The Diabetes Control and Complications Trial Research Group
-
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
-
(1993)
N Engl J Med
, vol.329
, Issue.14
, pp. 977-986
-
-
-
2
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UK Prospective Diabetes Study (UKPDS) Group
-
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
-
(1998)
Lancet
, vol.352
, Issue.9131
, pp. 837-853
-
-
-
3
-
-
0029147687
-
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
-
Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117.
-
(1995)
Diabetes Res Clin Pract
, vol.28
, Issue.2
, pp. 103-117
-
-
Ohkubo, Y.1
Kishikawa, H.2
Araki, E.3
-
4
-
-
0033055724
-
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
-
Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353(9153):617-622.
-
(1999)
Lancet
, vol.353
, Issue.9153
, pp. 617-622
-
-
Gaede, P.1
Vedel, P.2
Parving, H.-H.3
Pedersen, O.4
-
5
-
-
45149133036
-
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
-
ADVANCE Collaborative Group
-
Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
-
(2008)
N Engl J Med
, vol.358
, Issue.24
, pp. 2560-2572
-
-
Patel, A.1
Macmahon, S.2
Chalmers, J.3
-
6
-
-
0036231443
-
Gastric emptying in diabetes: Clinical significance and treatment
-
Horowitz M, O'Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med. 2002;19(3):177-194.
-
(2002)
Diabet Med
, vol.19
, Issue.3
, pp. 177-194
-
-
Horowitz, M.1
O'Donovan, D.2
Jones, K.L.3
Feinle, C.4
Rayner, C.K.5
Samsom, M.6
-
8
-
-
0031015510
-
Principles of drug administration in renal insufficiency
-
Lam YW, Banerjis S, Atfield C, et al. Principles of drug administration in renal insufficiency. Clin Pharm. 1997;32(1):30-57.
-
(1997)
Clin Pharm
, vol.32
, Issue.1
, pp. 30-57
-
-
Lam, Y.W.1
Banerjis, S.2
Atfield, C.3
-
9
-
-
58449085258
-
Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?
-
Haneda M, Morikawa A. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Nephrol Dial Transplant. 2009;24(2):338-341.
-
(2009)
Nephrol Dial Transplant
, vol.24
, Issue.2
, pp. 338-341
-
-
Haneda, M.1
Morikawa, A.2
-
10
-
-
84880103028
-
Evidence-based practice guidelines, standards, and related recommendations and documents for diabetes care
-
The American Diabetes Association's (ADA)
-
The American Diabetes Association's (ADA) Evidence-based practice guidelines, standards, and related recommendations and documents for diabetes care. Diabetes Care. 2012; 35(Suppl 1):13-57.
-
(2012)
Diabetes Care
, vol.35
, Issue.SUPPL. 1
, pp. 13-57
-
-
-
11
-
-
0005502850
-
The use of glycosylated hemoglobin in dialysis patients
-
Tzamaloukas AH. The use of glycosylated hemoglobin in dialysis patients. Semin Dial. 1998;11(3):141-143.
-
(1998)
Semin Dial
, vol.11
, Issue.3
, pp. 141-143
-
-
Tzamaloukas, A.H.1
-
12
-
-
34547486527
-
Diabetes management issues for patients with chronic kidney disease
-
Cavanaugh KL. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes. 2007;25(3): 90-97.
-
(2007)
Clin Diabetes
, vol.25
, Issue.3
, pp. 90-97
-
-
Cavanaugh, K.L.1
-
13
-
-
77951621021
-
Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis
-
Alberta Kidney Disease Network
-
Shurraw S, Majumdar SR, Thadhani R, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis. 2010;55(5):875-884.
-
(2010)
Am J Kidney Dis
, vol.55
, Issue.5
, pp. 875-884
-
-
Shurraw, S.1
Majumdar, S.R.2
Thadhani, R.3
Wiebe, N.4
Tonelli, M.5
-
14
-
-
0033631547
-
Impact of end-stage renal disease and dialysis on glycemic control
-
Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. 2000;13(1):4-8.
-
(2000)
Semin Dial
, vol.13
, Issue.1
, pp. 4-8
-
-
Mak, R.H.1
-
15
-
-
0018140320
-
Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin
-
DeFronzo RA, Tobin JD, Rowe JW, Andres R. Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest. 1978;62(2):425-435.
-
(1978)
J Clin Invest
, vol.62
, Issue.2
, pp. 425-435
-
-
Defronzo, R.A.1
Tobin, J.D.2
Rowe, J.W.3
Andres, R.4
-
16
-
-
0028028957
-
Abnormal leucine-induced insulin secretion in chronic renal failure
-
Oh HY, Fadda GZ, Smogorzewski M, Liou HH, Massry SG. Abnormal leucine-induced insulin secretion in chronic renal failure. Am J Physiol. 1994;267(5 Pt 2):F853-F860.
-
(1994)
Am J Physiol
, vol.267
, Issue.5 PART. 2
-
-
Oh, H.Y.1
Fadda, G.Z.2
Smogorzewski, M.3
Liou, H.H.4
Massry, S.G.5
-
18
-
-
0026771083
-
Glucose and insulin metabolism in uremia
-
Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron. 1992;61(4):377-382.
-
(1992)
Nephron
, vol.61
, Issue.4
, pp. 377-382
-
-
Mak, R.H.1
Defronzo, R.A.2
-
19
-
-
0026523822
-
Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients
-
Mak RH. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int. 1992;41(4):1049-1054.
-
(1992)
Kidney Int
, vol.41
, Issue.4
, pp. 1049-1054
-
-
Mak, R.H.1
-
20
-
-
35348917135
-
Management of glycemia in patients with diabetes mellitus and CKD
-
Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007;50(5):865-879.
-
(2007)
Am J Kidney Dis
, vol.50
, Issue.5
, pp. 865-879
-
-
Lubowsky, N.D.1
Siegel, R.2
Pittas, A.G.3
-
21
-
-
0021264112
-
Insulin pharmacokinetics
-
Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984;7(2):188-199.
-
(1984)
Diabetes Care
, vol.7
, Issue.2
, pp. 188-199
-
-
Binder, C.1
Lauritzen, T.2
Faber, O.3
Pramming, S.4
-
22
-
-
0035349026
-
Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients
-
Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001;24(5):886-890.
-
(2001)
Diabetes Care
, vol.24
, Issue.5
, pp. 886-890
-
-
Rave, K.1
Heise, T.2
Pfützner, A.3
Heinemann, L.4
Sawicki, P.T.5
-
23
-
-
0032792964
-
Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus
-
Aisenpreis U, Pfützner A, Giehl M, Keller F, Jehle PM. Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant. 1999;14(Suppl 4):5-6.
-
(1999)
Nephrol Dial Transplant
, vol.14
, Issue.SUPPL. 4
, pp. 5-6
-
-
Aisenpreis, U.1
Pfützner, A.2
Giehl, M.3
Keller, F.4
Jehle, P.M.5
-
24
-
-
84870597571
-
Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis
-
Toyoda M, Kimura M, Yamamoto N, et al. Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis. J Nephrol. 2012
-
(2012)
J Nephrol
-
-
Toyoda, M.1
Kimura, M.2
Yamamoto, N.3
-
25
-
-
0003403584
-
-
3rd ed. Philadelphia, Pa: American College of Physicians
-
Bennett WM, Aronoff GR, Golper TA, Morrison G, Brater DC, Singer I. In: Drug prescribing in renal failure: dosing guidelines for adults. 3rd ed. Philadelphia, Pa: American College of Physicians; 1994:93.
-
(1994)
Drug Prescribing In Renal Failure: Dosing Guidelines For Adults
, pp. 93
-
-
Bennett, W.M.1
Aronoff, G.R.2
Golper, T.A.3
Morrison, G.4
Brater, D.C.5
Singer, I.6
-
26
-
-
0026043119
-
Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: A review
-
Tzamaloukas AH, Oreopoulos DG. Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: a review. Adv Perit Dial. 1991;7(7):81-85.
-
(1991)
Adv Perit Dial
, vol.7
, Issue.7
, pp. 81-85
-
-
Tzamaloukas, A.H.1
Oreopoulos, D.G.2
-
27
-
-
0025341533
-
Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus
-
Coppack SW, Lant AF, McIntosh CS, Rodgers AV. Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. Br J Clin Pharmacol. 1990;29(6):673-684.
-
(1990)
Br J Clin Pharmacol
, vol.29
, Issue.6
, pp. 673-684
-
-
Coppack, S.W.1
Lant, A.F.2
McIntosh, C.S.3
Rodgers, A.V.4
-
28
-
-
0015698165
-
Pharmacokinetic of glipizide in man: Influence of renal insufficiency
-
Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J. Pharmacokinetic of glipizide in man: influence of renal insufficiency. Diabetologia. 1973;9(S1):331-338.
-
(1973)
Diabetologia
, vol.9
, Issue.S1
, pp. 331-338
-
-
Balant, L.1
Zahnd, G.2
Gorgia, A.3
Schwarz, R.4
Fabre, J.5
-
29
-
-
33845760213
-
KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease
-
National Kidney Foundation
-
National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2)(Suppl 2): 12-154.
-
(2007)
Am J Kidney Dis
, vol.49
, Issue.2 SUPPL. 2
, pp. 12-154
-
-
-
30
-
-
0029827893
-
Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients
-
Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res. 1996;28(9):434-439.
-
(1996)
Horm Metab Res
, vol.28
, Issue.9
, pp. 434-439
-
-
Rosenkranz, B.1
-
31
-
-
0029857682
-
Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment
-
Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39(12):1617-1624.
-
(1996)
Diabetologia
, vol.39
, Issue.12
, pp. 1617-1624
-
-
Rosenkranz, B.1
Profozic, V.2
Metelko, Z.3
Mrzljak, V.4
Lange, C.5
Malerczyk, V.6
-
32
-
-
0035904785
-
Insulinotropic meglitinide analogues
-
Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001;358(9294):1709-1716.
-
(2001)
Lancet
, vol.358
, Issue.9294
, pp. 1709-1716
-
-
Dornhorst, A.1
-
33
-
-
0028139101
-
Re-evaluation of a biguanide, metformin: Mechanism of action and tolerability
-
Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res. 1994;30(3):187-228.
-
(1994)
Pharmacol Res
, vol.30
, Issue.3
, pp. 187-228
-
-
Sirtori, C.R.1
Pasik, C.2
-
34
-
-
0032969589
-
Incidence of lactic acidosis in metformin users
-
Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22(6):925-927.
-
(1999)
Diabetes Care
, vol.22
, Issue.6
, pp. 925-927
-
-
Stang, M.1
Wysowski, D.K.2
Butler-Jones, D.3
-
35
-
-
48749096999
-
-
National Institute for Health and Clinical Excellence. NICE, Available at, Accessed May 2013
-
National Institute for Health and Clinical Excellence. NICE 2009. Type 2 Diabetes: The management of type 2 diabetes. NICE clinical guideline 87. Available at: http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf. Accessed May 2013.
-
(2009)
Type 2 Diabetes: The Management of Type 2 Diabetes. NICE Clinical Guideline
, pp. 87
-
-
-
36
-
-
84880089144
-
-
U.S. Food and Drug Administration, Available at, Accessed May 2013
-
U.S. Food and Drug Administration. Metformin. 2002. Available at: www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf. Accessed May 2013.
-
(2002)
Metformin
-
-
-
37
-
-
84876358992
-
Metformin in patients with chronic kidney disease: Strengths and weaknesses
-
Rocha A, Almeida M, Santos J, Carvalho A. Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol. 2013;26(1):55-60.
-
(2013)
J Nephrol
, vol.26
, Issue.1
, pp. 55-60
-
-
Rocha, A.1
Almeida, M.2
Santos, J.3
Carvalho, A.4
-
38
-
-
33746371464
-
Protection of the Kidney by thiazolidinediones: An assessment from bench to bedside
-
Sarafidis PA, Bakris GL. Protection of the Kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006;70(7):1223-1233.
-
(2006)
Kidney Int
, vol.70
, Issue.7
, pp. 1223-1233
-
-
Sarafidis, P.A.1
Bakris, G.L.2
-
39
-
-
67149146438
-
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
-
RECORD Study Team
-
Home PD, Pocock SJ, Beck-Nielsen H, et al. RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135.
-
(2009)
Lancet
, vol.373
, Issue.9681
, pp. 2125-2135
-
-
Home, P.D.1
Pocock, S.J.2
Beck-Nielsen, H.3
-
40
-
-
0037705723
-
Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis
-
Manley HJ, Pharm D, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy. 2003;2(7):861-865.
-
(2003)
Pharmacotherapy
, vol.2
, Issue.7
, pp. 861-865
-
-
Manley, H.J.1
Pharm, D.2
Allcock, N.M.3
-
41
-
-
33846006173
-
The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.
-
(2006)
Lancet
, vol.368
, Issue.9548
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
42
-
-
33645533439
-
Exenatide: From Gila monster to the pharmacy
-
Triplitt C, Chiquette E. Exenatide: from Gila monster to the pharmacy. J Am Pharm Assoc (2003). 2006;46(1):44-52.
-
(2006)
J Am Pharm Assoc (2003)
, vol.46
, Issue.1
, pp. 44-52
-
-
Triplitt, C.1
Chiquette, E.2
-
43
-
-
34548034895
-
Effect of renal impairment on the pharmacokinetics of exenatide
-
Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clinl Pharmacol. 2007;64(3):317-327.
-
(2007)
Br J Clinl Pharmacol
, vol.64
, Issue.3
, pp. 317-327
-
-
Linnebjerg, H.1
Kothare, P.A.2
Park, S.3
-
44
-
-
45449105789
-
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
-
Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545-555.
-
(2008)
Diabetes Obes Metab
, vol.10
, Issue.7
, pp. 545-555
-
-
Chan, J.C.1
Scott, R.2
Arjona, F.J.C.3
-
45
-
-
79961222810
-
Pharmacology of dipeptidyl peptidase-4 inhibitors: Similarities and differences
-
Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71(11): 1441-1467.
-
(2011)
Drugs
, vol.71
, Issue.11
, pp. 1441-1467
-
-
Baetta, R.1
Corsini, A.2
-
47
-
-
84880107782
-
-
Novartis Pharmaceutical UK Ltd, Available at, Accessed 25 May 2011
-
Novartis Pharmaceutical UK Ltd. Summary of product characteristics 'Galvus 50 mg tablets'. 2011. Available at: www.medicines.org.uk/EMC. Accessed 25 May 2011.
-
(2011)
Summary of Product Characteristics 'Galvus 50 Mg Tablets'
-
-
-
48
-
-
78650724091
-
Incretin-based therapies in complex patients: Practical implications and opportunities for maximizing clinical outcomes: A discussion with Dr. Vivian A. Fonseca
-
Fonseca VA. Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca. Am J Med. 2011;124(Suppl 1):54-61.
-
(2011)
Am J Med
, vol.124
, Issue.SUPPL. 1
, pp. 54-61
-
-
Fonseca, V.A.1
-
49
-
-
84858011452
-
Pharmacology, efficacyy, and safety of linagliptin for the treatment of type 2 diabetes mellitus
-
Neumiller JJ. Pharmacology, efficacyy, and safety of linagliptin for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2012;46(3):358-367.
-
(2012)
Ann Pharmacother
, vol.46
, Issue.3
, pp. 358-367
-
-
Neumiller, J.J.1
|